|Articles|April 10, 2018
Shanghai HEP Pharma Signs Agreement with OmniComm Systems
Advertisement
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
4
SCOPE X: What Real-Time Patient Data Is Doing to ClinOps Efficiency
5